Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5865 Articles

Chris Lange | May 5, 2016 at 12:05 PM EDT

Oncobiologics Closes in on Market Entrance With Most Recent IPO Filing

Oncobiologics expects to price 5 million shares within the range of $11 to $13 per share in an initial public…

Paul Ausick | May 5, 2016 at 7:45 AM EDT

Merck Earnings Beat Estimates; More Acquisitions on Tap

Drug giant Merck reported mixed first-quarter 2016 results before markets opened Thursday morning.

Trey Thoelcke | May 5, 2016 at 7:35 AM EDT

3 Big Pharma Stocks With Credible Threats to Their Blockbusters

A pharmaceutical company could face a threat to one of its products for a number of reasons, ranging from an…

Jon C. Ogg | May 4, 2016 at 11:25 AM EDT

Why Credit Suisse’s Neutral Rating on Teva Almost Sounds Like a Buy Rating

Credit Suisse's new Neutral rating on Teva Pharmaceutical Industries actually comes with significant upside.

Chris Lange | May 4, 2016 at 10:05 AM EDT

Humana Earnings Beat Estimates but Fail to Impress Investors

Humana reported better-than-expected first-quarter financial results before the markets opened on Wednesday.

Chris Lange | May 3, 2016 at 1:35 PM EDT

Can Gilead Shares Still Really Rise to $150?

Gilead Sciences saw a sell-off after the company posted less than favorable earnings, but one analyst thinks that investors have…

Chris Lange | May 3, 2016 at 11:25 AM EDT

Viamet Pharma Announces Potential Pricing for IPO

Viamet Pharmaceuticals intends to price more than 5 million shares within the range of $14 to $16 per share for…

Trey Thoelcke | May 3, 2016 at 9:05 AM EDT

3 Underfollowed Infectious Disease Stocks That Deserve More Attention

Infectious diseases always have been a hot topic in biotech, but over the past half decade more capital has been…

Paul Ausick | May 3, 2016 at 7:25 AM EDT

Pfizer Boosts Guidance With Help From Hospira, Weaker Dollar

Pfizer reported better-than-expected first-quarter 2016 results before markets opened Tuesday morning.

Douglas A. McIntyre | May 3, 2016 at 6:57 AM EDT

The 5 Thinnest States in America

Only five states had residents with Body Mass Index (BMI) at or below the range considered normal, according to CDC…

Jon C. Ogg | May 2, 2016 at 4:35 PM EDT

Can Shares of Aeglea BioTherapeutics Really More Than Double?

Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) has only been public for a few weeks, but the analysts from its underwriting syndicate…

Chris Lange | May 2, 2016 at 12:15 PM EDT

What to Expect From Pfizer Earnings

Pfizer is scheduled to report its first-quarter financial results before the markets open on Tuesday.

Chris Lange | May 1, 2016 at 10:50 AM EDT

Analysts Make Major Changes to Top Biotech Ratings

With earnings having just been released for some of the top biotech companies, we saw a flurry of analyst calls…

Chris Lange | May 1, 2016 at 10:15 AM EDT

How Analysts View Vertex After Earnings

One portfolio manager on CNBC noted that Vertex could end up being an acquisition target ahead, without mentioning any specifics.

Paul Ausick | May 1, 2016 at 9:40 AM EDT

Did Molina Healthcare’s Future Just Get Compromised?

Molina Healthcare to a real beating after reporting a bad miss on first-quarter earnings. The stock was down nearly 20%…

1 … 212 213 214 215 216 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Oncobiologics Closes in on Market Entrance With Most Recent IPO Filing

Merck Earnings Beat Estimates; More Acquisitions on Tap

3 Big Pharma Stocks With Credible Threats to Their Blockbusters

Why Credit Suisse’s Neutral Rating on Teva Almost Sounds Like a Buy Rating

Humana Earnings Beat Estimates but Fail to Impress Investors

Can Gilead Shares Still Really Rise to $150?

Viamet Pharma Announces Potential Pricing for IPO

3 Underfollowed Infectious Disease Stocks That Deserve More Attention

Pfizer Boosts Guidance With Help From Hospira, Weaker Dollar

The 5 Thinnest States in America

Can Shares of Aeglea BioTherapeutics Really More Than Double?

What to Expect From Pfizer Earnings

Analysts Make Major Changes to Top Biotech Ratings

How Analysts View Vertex After Earnings

Did Molina Healthcare’s Future Just Get Compromised?

The DOJ just charged 324 defendants in the largest Medicare fraud takedown ever — $14.6 billion that’s now reaching retirees’ statements

Which Big-Box Store Chain Has Dominated 2026: Walmart, Target, or Costco?

A $360,000 Portfolio That Quietly Pays You More Than the Average Social Security Check

The DOJ just charged 324 defendants in the largest Medicare fraud takedown ever — $14.6 billion that's now reaching retirees' statements

A $360,000 Portfolio That Quietly Pays You More Than the Average Social Security Check

The DOJ just charged 324 defendants in the largest Medicare fraud takedown ever — $14.6 billion that’s now reaching retirees’ statements

Live: Navitas Semiconductor Q1 Earnings Tonight. Can the 676% Surge Survive the Print?

Health and Healthcare Articles

All Health and Healthcare Articles

Oncobiologics Closes in on Market Entrance With Most Recent IPO Filing

Merck Earnings Beat Estimates; More Acquisitions on Tap

3 Big Pharma Stocks With Credible Threats to Their Blockbusters

Why Credit Suisse’s Neutral Rating on Teva Almost Sounds Like a Buy Rating

Humana Earnings Beat Estimates but Fail to Impress Investors

Can Gilead Shares Still Really Rise to $150?

Viamet Pharma Announces Potential Pricing for IPO

3 Underfollowed Infectious Disease Stocks That Deserve More Attention

Pfizer Boosts Guidance With Help From Hospira, Weaker Dollar

The 5 Thinnest States in America

Can Shares of Aeglea BioTherapeutics Really More Than Double?

What to Expect From Pfizer Earnings

Analysts Make Major Changes to Top Biotech Ratings

How Analysts View Vertex After Earnings

Did Molina Healthcare’s Future Just Get Compromised?

The DOJ just charged 324 defendants in the largest Medicare fraud takedown ever — $14.6 billion that’s now reaching retirees’ statements

Which Big-Box Store Chain Has Dominated 2026: Walmart, Target, or Costco?

A $360,000 Portfolio That Quietly Pays You More Than the Average Social Security Check

Featured Reads

The DOJ just charged 324 defendants in the largest Medicare fraud takedown ever — $14.6 billion that's now reaching retirees' statements

A $360,000 Portfolio That Quietly Pays You More Than the Average Social Security Check